Citations

Showing 10 of 108094 citations.

Dynamic 2D self‐phase‐map Nyquist ghost correction for simultaneous multi‐slice echo planar imaging
Yarach, Uten , Tung, Yi‐Hang , Setsompop, Kawin , In, Myung‐Ho , Chatnuntawech, Itthi , Yakupov, Renat , Godenschweger, Frank, Speck, Oliver , In, Myung-Ho

Mayo Clinic

Magnetic Resonance in Medicine | February 10, 2018 | Volume: 80 | Issue: 4 | Pages: 1577-1587

10.1002/mrm.27123 | PMID 29427393 Get It

PurposeTo develop a reconstruction pipeline that intrinsically accounts for both simultaneous multislice echo planar imaging (SMS‐EPI) reconstruction and dynamic slice‐specific Nyquist ghosting correction in time‐series data.MethodsAfter 1D slice‐group average phase correction, the separate polarity (i.e., even and odd echoes) SMS‐EPI data were unaliased by slice GeneRalized Autocalibrating Partial Parallel Acquisition. Both the slice‐unaliased even and odd echoes were jointly reconstructed using a model‐based framework, extended for SMS‐EPI reconstruction that estimates a 2D self‐phase map, corrects dynamic slice‐specific phase errors, and combines data from all coils and echoes to obtain the final images.ResultsThe percentage ghost‐to‐signal ratios (%GSRs) and its temporal variations for MB3Ry2 with a field of view/4 shift in a human brain obtained by the proposed dynamic 2D and standard 1D phase corrections were 1.37 ± 0.11 and 2.66 ± 0.16, respectively. Even with a large regularization parameter λ applied in the proposed reconstruction, the smoothing effect in fMRI activation maps was comparable to a very small Gaussian kernel size 1 × 1 × 1 mm3.ConclusionThe proposed reconstruction pipeline reduced slice‐specific phase errors in SMS‐EPI, resulting in reduction of GSR. It is applicable for functional MRI studies because the smoothing effect caused by the regularization parameter selection can be minimal in a blood‐oxygen‐level–dependent activation map.
FEV1 reversibility for asthma diagnosis: a critical evaluation
Ye, Qian , Liao, Amy , D’Urzo, Anthony

Mayo Clinic

Expert Review of Respiratory Medicine | February 10, 2018 | Volume: 12 | Issue: 4 | Pages: 265-267

10.1080/17476348.2018.1439741 | PMID 29426266 Get It

High-resolution esophageal manometry in a Mexican population: diagnostic outcome
Hernández-González, L E, Achem, S. R., Vázquez‐Elizondo, Genaro

Mayo Clinic

Diseases of the Esophagus | February 10, 2018 | Volume: 31 | Issue: 6 | Pages: No page available

10.1093/dote/dox159 | PMID 29444254 Get It

Non-tender recurrent scrotal cellulitis
Abeykoon, Jithma P. , Enzler, Mark J., Enzler, Mark, Paludo, Jonas

Mayo Clinic

Postgraduate Medical Journal | February 9, 2018 | Volume: 94 | Issue: 1111 | Pages: 310-310

10.1136/postgradmedj-2017-135170 | PMID 29440333 Get It

Leukocyte Telomere Length and Pancreatic Cancer Risk
Antwi, Samuel O. , Petersen, Gloria M. , Antwi, Samuel O

Mayo Clinic

Pancreas | February 9, 2018 | Volume: 47 | Issue: 3 | Pages: 265-271

10.1097/mpa.0000000000000995 | PMID 29424808 Get It

Abstract Many risk factors have been firmly established for pancreatic cancer (PC), but the molecular processes by which known risk factors influence susceptibility to PC are not clear. There has been a recent upsurge of interest in the role of telomere length (TL), the protective DNA sequence repeats at chromosome ends, in pancreatic carcinogenesis. Given this heightened interest, we performed an in-depth, focused, and up-to-date review of the epidemiological evidence linking leukocyte TL (LTL) with PC risk. We searched MEDLINE, Embase, and the Cochrane Library databases for all published studies on LTL and PC risk, up to May 2017. Five studies were identified for review: 4 nested case-control studies and 1 retrospective case-control study. Two studies found opposite associations between LTL and PC risk: 1 found a dose-response positive association and the other found a dose-response inverse association. Two studies also found a “U-shaped” association, whereas another reported a weak nonlinear relationship. We offer potential reasons for the conflicting findings including variation in study design, biospecimen characteristics, and differences in interlaboratory measurements of TL. Future studies should carefully control for risk factors of PC that are associated also with telomere attrition and investigate the role of genetic variation in TL maintenance.
Mayo CALR mutation type classification guide using alpha helix propensity
Finke, Christy M. , Tischer, Alexander , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L. , Tefferi, Ayalew , Tischer, Alexander

Mayo Clinic

American Journal of Hematology | February 9, 2018 | Volume: 93 | Issue: 5 | Pages: No page available

10.1002/ajh.25065 | PMID 29424450 Get It

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
Lang, Jessica D. , Hendricks, William P.D. , Orlando, Krystal A. , Yin, Hongwei , Kiefer, Jeffrey , Sharma, Ritin , Pirrotte, Patrick , Raupach, Elizabeth A. , Sereduk, Chris , Tang, Nanyun , Liang, Winnie S. , Washington, Megan , Facista, Salvatore , Zismann, Victoria , Major, Michael B. , Sekulić, Aleksandar , Hass, Ralf , Nair, Praveen , Weissman, Bernard E. , Huntsman, David G. , Trent, Jeffrey M. , Ramos, Pilar , Cousins, Emily M. , Wang, Yemin , Karnezis, Anthony N. , Vanderhyden, Barbara C. , Lang, Jessica D.

Mayo Clinic

Clinical Cancer Research | February 9, 2018 | Volume: 24 | Issue: 8 | Pages: 1932-1943

10.1158/1078-0432.ccr-17-1928 | PMID 29440177 Get It

Abstract Purpose: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer in young women that is universally driven by loss of the SWI/SNF ATPase subunits SMARCA4 and SMARCA2. A great need exists for effective targeted therapies for SCCOHT. Experimental Design: To identify underlying therapeutic vulnerabilities in SCCOHT, we conducted high-throughput siRNA and drug screens. Complementary proteomics approaches profiled kinases inhibited by ponatinib. Ponatinib was tested for efficacy in two patient-derived xenograft (PDX) models and one cell-line xenograft model of SCCOHT. Results: The receptor tyrosine kinase (RTK) family was enriched in siRNA screen hits, with FGFRs and PDGFRs being overlapping hits between drug and siRNA screens. Of multiple potent drug classes in SCCOHT cell lines, RTK inhibitors were only one of two classes with selectivity in SCCOHT relative to three SWI/SNF wild-type ovarian cancer cell lines. We further identified ponatinib as the most effective clinically approved RTK inhibitor. Reexpression of SMARCA4 was shown to confer a 1.7-fold increase in resistance to ponatinib. Subsequent proteomic assessment of ponatinib target modulation in SCCOHT cell models confirmed inhibition of nine known ponatinib target kinases alongside 77 noncanonical ponatinib targets in SCCOHT. Finally, ponatinib delayed tumor doubling time 4-fold in SCCOHT-1 xenografts while reducing final tumor volumes in SCCOHT PDX models by 58.6% and 42.5%. Conclusions: Ponatinib is an effective agent for SMARCA4-mutant SCCOHT in both in vitro and in vivo preclinical models through its inhibition of multiple kinases. Clinical investigation of this FDA-approved oncology drug in SCCOHT is warranted. Clin Cancer Res; 24(8); 1932–43. ©2018 AACR.
Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome
Carey, William A., Weaver, Amy L. , Mara, Kristin C. , Clark, Reese H. , Mara, Kristin C

Mayo Clinic

Pediatrics | February 9, 2018 | Volume: 141 | Issue: 3 | Pages: No page available

10.1542/peds.2017-3108 | PMID 29439205 Get It

BACKGROUND: Inhaled nitric oxide (iNO) is increasingly prescribed to extremely premature neonates with respiratory distress syndrome (RDS). Most of this off-label use occurs during the first week of life. We studied this practice, hypothesizing that it would not be associated with improved survival. METHODS: We queried the Pediatrix Medical Group Clinical Data Warehouse to identify all neonates born at 22 to 29 weeks’ gestation from 2004 to 2014. In our study sample, we included singletons who required mechanical ventilation for treatment of RDS and excluded those with anomalies. The primary outcome was death before discharge. Through a sequential risk set approach, each patient who received iNO during the first 7 days of life (“case patient”) was matched by using propensity scores to a patient who had not received iNO at a chronological age before the case patient’s iNO initiation age (defined as the index age for the matched pair). The association between iNO status and in-hospital mortality was evaluated in a Cox proportional hazards regression model by using age as the time scale with patients entering the risk set at their respective index age. RESULTS: Among 37 909 neonates in our study sample, we identified 993 (2.6%) who received iNO. The 2 matched cohorts each contained 971 patients. We did not observe a significant association between iNO exposure and mortality (hazard ratio, 1.08; 95% confidence interval, 0.94–1.25; P = .29). CONCLUSIONS: Off-label prescription of iNO is not associated with reduced in-hospital mortality among extremely premature neonates with RDS.